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ABSTRACT
Objective To assess the impact of home
telemonitoring on health service use and quality of life
in patients with severe chronic lung disease.
Design Randomised crossover trial with 6 months of
standard best practice clinical care (control group) and
6 months with the addition of telemonitoring.
Participants 68 patients with chronic lung disease (38
with COPD; 30 with chronic respiratory failure due to
other causes), who had a hospital admission for an
exacerbation within 6 months of randomisation and
either used long-term oxygen therapy or had an arterial
oxygen saturation (SpO2) of <90% on air during the
previous admission. Individuals received telemonitoring
(second-generation system) via broadband link to a
hospital-based care team.
Outcome measures Primary outcome measure was
time to ﬁrst hospital admission for an acute
exacerbation. Secondary outcome measures were
hospital admissions, general practitioner (GP)
consultations and home visits by nurses, quality of life
measured by EuroQol-5D and hospital anxiety and
depression (HAD) scale, and self-efﬁcacy score
(Stanford).
Results Median (IQR) number of days to ﬁrst admission
showed no difference between the two groups—77
(114) telemonitoring, 77.5 (61) control (p=0.189).
Hospital admission rate at 6 months increased (0.63
telemonitoring vs 0.32 control p=0.026). Home visits
increased during telemonitoring; GP consultations were
unchanged. Self-efﬁcacy fell, while HAD depression score
improved marginally during telemonitoring.
Conclusions Telemonitoring added to standard care
did not alter time to next acute hospital admission,
increased hospital admissions and home visits overall,
and did not improve quality of life in chronic respiratory
patients.
Trial registration number NCT02180919
(ClinicalTrials.gov).
BACKGROUND
Telemonitoring has been advocated in a variety of
chronic conditions including chronic heart failure,
diabetes, and COPD, with the goal of reducing hos-
pital admissions, improving self-care and enhancing
quality of life. In patients with chronic heart
failure, a systematic review and meta-analysis1 sug-
gested that remote home monitoring reduced
admissions to hospital and all-cause mortality while
improving quality of life, but subsequent larger ran-
domised controlled trials in the USA2 and
Germany3 showed no advantage to the addition of
telemonitoring to usual care on a range of primary
endpoints including mortality and all-cause
admissions.
COPD affects around three million individuals in
the UK and is the second commonest cause of hos-
pital admission. A third of patients are readmitted
within three months of discharge following an
acute exacerbation.4 A Italian randomised trial5 of
tele-assistance in chronic respiratory patients requir-
ing long-term oxygen therapy (LTOT) or home
mechanical ventilation showed 36% fewer hospita-
lisations or general practitioner (GP) calls, and
reduction in healthcare costs in the telemonitoring
group, with the effect more pronounced in patients
with COPD. In Bilbao, Spain, telemonitoring in
COPD and heart failure resulted in a greater pro-
portion of patients without an admission over
12 months.6 A Cochrane review and meta-analysis
of telemonitoring in COPD in 20127 found a
decrease in hospitalisations and visits to the emer-
gency room but no impact on quality of life. This
was followed by the Whole Systems Demonstrator
(WSD) trial in the UK, which compared usual care
versus addition of telemonitoring in patient groups
with COPD, heart failure and diabetes. Initial head-
line reports8 showed a reduction in mortality, emer-
gency admissions, bed days and tariff cost, but
subsequent analysis found no change in quality of
life for patients, and no quality-adjusted life-year
gain from telemonitoring compared with standard
care alone.9
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Key messages
What is the key question?
▸ Does telemonitoring reduce healthcare
demands and improve health-related quality of
life in patients with severe chronic respiratory
disease?
What is the bottom line?
▸ Telemonitoring did not delay time to next acute
hospital admission for an exacerbation,
increased health service usage and did not
improve quality of life.
Why read on?
▸ To ﬁnd out why telemonitoring may increase
healthcare activity.
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More recently, a randomised trial of telemonitoring versus
usual care using a broadband system in COPD patients in
Scotland showed no change in time to admission for next
exacerbation, frequency of admissions or quality of life with
telemonitoring.10
Despite these negative outcomes, telecare is being advocated
to assist a shift from acute hospital management to greater care
in the community and has already attracted considerable health
service investment.11 We reasoned that the addition of telemoni-
toring in a group of severe respiratory patients might reduce
healthcare activity by improving the patients’ ability to identify
exacerbations and carry out self-care. So in order to clarify the
role of telehealth in a severe chronic respiratory cohort, we
carried out a trial of telemonitoring to determine effects on hos-
pitalisation, healthcare utilisation and quality of life.
METHODS
The TeleCRAFT trial (ClinicalTrials.gov identiﬁer
NCT02180919) was a randomised crossover study with
6 months telemonitoring and 6 months control period. Patients
were recruited from outpatients and inpatients at Royal
Brompton & Hareﬁeld NHS Foundation Trust, London SW3,
West Middlesex University Hospital, Hounslow, Middlesex,
TW7, and St George’s University Hospital, London, SW17,
over the period July 2009 to July 2011. Management was
carried out by a combination of allied health professionals, pre-
dominantly clinical nurses in the hospital who were aware of
allocation to telemonitoring or control group and who liaised
with primary care teams. Analysis was carried out blind to trial
limb participation. Telemonitoring occurred during the hours
09:00–17:00 Monday through Friday, similar to the protocol of
Vitacca et al.5 Outside these hours, patients continued to use
their personalised management plan and could call the on-call
senior respiratory hospital doctor or primary care team for
further advice.
Patients
We recruited patients aged 18 years and above with COPD or
chronic respiratory failure due to another chronic respiratory
disorder (eg, bronchiectasis, chest wall disease, neuromuscular
disorder), who had been admitted with an infective exacerba-
tion of their chronic lung disease within the previous six months
and who fulﬁlled criteria for LTOT12 or who had an arterial
oxygen saturation (SpO2) level of ≤90% on air during the previ-
ous admission. The rationale for this was to enable home SpO2
monitoring to be a realistic marker of acute deterioration in
clinical status. The diagnosis of COPD or respiratory failure due
to another cause was conﬁrmed by a specialist respiratory
physician.
Exclusion criteria were cognitive impairment sufﬁcient to
impair understanding of the trial or interfere with use of tele-
monitoring, and age <18 years. Patients meeting eligibility cri-
teria who consented to participation were included in the trial
(see consort diagram in ﬁgure 1). An exacerbation was deﬁned
as a sustained worsening in respiratory condition, beyond
day-to-day variation, necessitating a change in therapy.
Patients were randomised to telemonitoring or delayed tele-
monitoring (control group), stratiﬁed for COPD or non-COPD
diagnosis in blocks of ﬁve with results generated and made avail-
able from our statistics unit. Prior to randomisation, treatment
was optimised including non-invasive ventilation (NIV) settings
and O2 ﬂow rate where applicable, to ensure stability as far as
possible.
Patients with chronic heart failure were recruited in a parallel
telemonitoring trial; this cohort was not part of this respiratory
crossover trial, and results will be reported elsewhere.
The primary outcome measure was time to ﬁrst hospital
admission for an acute exacerbation. Exacerbations were charac-
terised as deﬁned either as a self-reported exacerbation; an
episode of taking antibiotics and/or steroids in the control limb,
or in the telemonitoring limb a decrease in SpO2 with or
without a change in sputum production or colour or increase
breathlessness that prompted antibiotic and/or steroid therapy.
Hospital admissions for respiratory exacerbations were con-
ﬁrmed by review of the hospital discharge summary or the
patient’s notes.
Secondary outcome measures were hospital admissions, GP
consultations, home visits and hospitalisations for non-
respiratory causes, expressed as rates per 6 months. We also
assessed aspects of health-related quality of life by the hospital
anxiety and depression score (HADS),13 EuroQol-5D (EQ-
5D)14 and self-efﬁcacy using the Stanford self-efﬁcacy scale.15
Hospital and health visits were tallied at the end of each month
from patient diary cards (control limb) and information logged
into the telemonitoring system (telemonitoring limb). Any query
on the nature of healthcare visit in both trial limbs was clariﬁed
by follow-up phone call. HADS, EuroQol 5D and self-efﬁcacy
score were measured at 0, 3 and 6 months in each trial limb.
Telemonitoring was carried out in the patient’s home using
the Philips Motiva system (Phillips Healthcare, Guilford, Surrey,
UK) that comprises heart rate monitoring, ﬁnger pulse oximeter,
weight scales and blood pressure monitor. The system requests
daily responses to a questionnaire on breathlessness, wheeze,
sputum production, sleep quality and therapy alterations, for
example, a course of prednisolone started, LTOT ﬂow rate
increased. The symptom questionnaire responses, heart rate and
SpO2 were recorded daily, and blood pressure and weight were
measured once a week. These inputs were linked to the patient’s
television screen as an additional television channel that was
accessed by hand-held remote. Each patient received education
by the Philips Motiva team in using the monitoring devices
until he or she and/or family/carer felt fully conﬁdent using it.
Patients/careers completed a satisfaction questionnaire on ease
of use.
Data from the monitors were delivered to the healthcare team
members’ personal computer using a dedicated broadband line
that was installed in each patient’s home and routed via a secure
Philips Server. Results were reviewed daily by a healthcare team
member (Monday–Friday) by 14:00. These results from each
patient daily questionnaire, heart rate and SpO2 reading were
used to create an individualised trafﬁc light warning system such
that if all parameters were satisfactory this appeared as a green
light; or, for example, if a drop in SpO2 and increase in wheeze,
or increased breathlessness is seen, the telemonitoring system
generated a red light for that patient, which required action by
monitoring staff. The system is interactive, and therefore, the
healthcare team member can advise the patient through their
screen or by telephone (eg, start antibiotic, increase broncho-
dilator use), or provide educational material, for example, on
inhaler use or exercise; and patients can respond. Any SpO2 or
heart rate reading outside the patient’s preset set limits was
compared with the patient’s previous data and linked to
symptom changes. Therefore, actions depended on a combin-
ation of symptoms, telemonitoring results and clinical judge-
ment. If the nurse was not sure what action to take, the advice
of a hospital consultant or GP was sought. If patients failed to
respond to measures suggested by initial telephone advice, or
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their condition was deteriorating rapidly, they were advised to
contact their GP (and management discussed with GP). If it was
deemed more appropriate by the telephone consult, a home
visit by the patient’s community/primary care nursing team or
hospital visit was arranged. Via the telemonitoring system,
patients were questioned weekly on whether they had consulted
their GP, had a home visit, attended the Accident and
Emergency Department or been admitted to hospital. For over-
night and weekend health problems, each patient continued to
use a personal management plan as described below. Where
weekend exacerbations were reported, a phone call was carried
out the following Monday.
Standard care
Patients were managed in accordance with conventional guide-
lines.12 16 Each patient was provided with a rescue pack (anti-
biotics and prednisolone) where indicated. Patients with COPD
had already completed a course of pulmonary rehabilitation
and, where indicated, had undergone a smoking cessation pro-
gramme. Any patient on NIV underwent a sleep study to opti-
mise ventilator settings. Oxygen was provided in accordance
with current guidelines.12 16 Each patient had a personalised
home care plan for escalating therapy with instructions regard-
ing antibiotic therapy, corticosteroid treatment and adjustment
of inhaled medication. Patients were provided with a contact
number of their medical team and also had ready access to
respiratory care nurses that were part of the trial, and their GP.
Sample size calculation
To assess time to hospital admission for an acute exacerbation
(ﬁrst readmission), we used the results of Vitacca et al5 and pre-
vious experience. To detect a difference of 25% in median time
to admission (median 120 days vs 150 days), using within-
patient SD of 60 days, signiﬁcance level 0.05 and power 0.8, a
sample size of 63 is required. To allow 10% dropout rate, 69
patients are required.
Analysis
Paired t tests were used to compare hospital admissions and sec-
ondary outcome measures during control and telemonitoring
limb. Further, McNemar’s tests were conducted stratifying by
COPD and respiratory failure groups to investigate potential
group differences. Unpaired t tests were used to compare
periods (‘control ﬁrst, telemonitoring second’ and ‘telemonitor-
ing ﬁrst, control second’ limbs). Results that were not normally
distributed are presented as median and IQR.
RESULTS
Trial recruitment
Seventy-three respiratory patients were recruited, the majority at
Royal Brompton & Hareﬁeld NHS Foundation Trust, of which
39 had COPD and 34 chronic respiratory failure. Recruitment
began in July 2009, and the trial was completed in July 2013.
Seventy-two patients were randomised, 38 (19 COPD) to
Figure 1 Consort diagram; analysis
was on an intention-to-treat basis.
Table 1 Baseline demographics
COPD Non-COPD All
Mean (SD) Mean (SD) Mean (SD)
Age (years) 65.3 (7.6) 58 (14.4) 61.8 (11.9)
FEV1 (L) 0.9 (0.5) 0.7 (0.5) 0.9 (0.5)
FVC (L) 2.1 (0.9) 1.1 (0.6) 1.7 (1)
PaO2 (kPa) 8.4 (1.2) 8.2 (1.4) 8.3 (1.3)
PaCO2 (kPa) 6.4 (1.3) 6.9 (1.3) 6.7 (1.3)
SpO2 (%) 92 (3) 89 (6) 90.4 (4.9)
MRC dyspnoea scale 4 (1) 4 (1) 4 (1)
Gold (stage) 3 (1) NA (NA) NA (NA)
Height (cm) 167 (8) 160 (12) 164 (11)
Weight (kg) 85 (26) 83.1 (38.2) 84.4 (31.9)
BMI (kg/m2) 31 (9) 33.9 (14.3) 32 (11.5)
HADS anxiety score 8 (4) 10 (4) 9 (4)
HADS depression score 7 (4) 8 (4) 8 (1)
EQ-5D scale score 57 (16) 57 (21) 57 (18)
N (%) N (%) N (%)
Males 20 (63) 9 (32) 29 (48)
NIV 27 (84) 25 (89) 52 (87)
LTOT 19 (59) 19 (68) 38 (63)
Lives alone 9 (28) 10 (36) 19 (32)
BMI, body mass index; HADS, hospital anxiety and depression score; LTOT, long-term
oxygen therapy; MRC, Medical Research Council; NIV, non-invasive ventilation.
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telemonitoring ﬁrst and 34 (20 COPD) to control group ﬁrst.
As per consort diagram (ﬁgure 1), 67 patients completed the
ﬁrst limb and at 12 months, analysis was completed in 61
patients (32 COPD). Baseline demographics of patient groups
are shown in table 1. Individual baseline demographics for each
patient can be found in online supplementary data.
Comorbidities are shown in table 2.
Hospital admissions for exacerbations
Time to ﬁrst acute respiratory exacerbation requiring hospitalisa-
tion did not differ between telemonitoring and control limb
overall. Of the subjects who experienced an event in both limbs,
the median (IQR) days to hospitalisation was 77.5 (61) versus
77 (114) in control and telemonitoring groups, respectively
(McNemar’s test p=0.189). Figure 2A shows a Kaplan–Meier
plot of the time free of hospitalisation in the control and tele-
monitoring groups. Figure 2B, which shows a Kaplan–Meier
plot of the time free of hospitalisation in the patients with
COPD and non-COPD patients, indicates no difference between
these subgroups.
Respiratory admissions for acute exacerbations at 6 months
increased in the group receiving telemonitoring—frequency
0.32 control versus 0.63 telemonitoring (mean difference 0.32,
p=0.026), although this number is small (table 3). There was
no evidence of a difference between patients with COPD and
non-COPD patients for respiratory admissions (p=0.955).
Home visits over 6 months increased (frequency 0.75 control
vs 4.00 telemonitoring, p<0.01) during the telemonitoring
period, but there was no change in frequency of GP visits and
no difference in hospital visits or non-respiratory cause hospital
admissions between trial limbs (p=0.933). The results of
unpaired t tests provide support for the assumption of no
period or order effect, with no evidence to suggest a period
effect for primary or secondary outcome variables.
EQ-5D scores (in total and for individual questions) and
EQ-5D scale did not differ between groups, HAD anxiety score
was also similar but HAD depression score showed overall
improvement in patients receiving telemonitoring compared
with the control group (table 4). However, these differences are
small and occur in patients in whom depression score is within
the normal range and do not exceed the minimally clinical
important difference (MCID) in other clinical circumstances.17
In a subgroup with a HADS depression score of >11, there was
a greater fall during telemonitoring but the number in this
group was small and so of doubtful clinical value.
Stanford self-efﬁcacy score
The self-efﬁcacy score declined when telemonitoring was used
in comparison to the control group for the total patient cohort
(table 4). However, there was no evidence of a difference in the
effects in the COPD and non-COPD groups (p=0.290). The
MCID of Stanford score is not well established in this patient
group, so clinical relevance may be minor. However, at best,
there is no evidence that the patients’ self-efﬁcacy improved
during telemonitoring.
There was a relatively low mortality rate. Five patients died
(see ﬁgure 1). All deaths occurred in an acute respiratory ward
during an exacerbation. Each of these patients had an agreed
ceiling of care of NIV, apart from one patient with a Do Not
Attempt Resuscitation order who had a cardiorespiratory arrest
and died in the Emergency Room. There was no difference
between the telemonitoring and standard care groups.
All patients successfully used the telemonitoring system, and
in no case did we detect that telemonitoring delayed admission,
or caused harm. Via the questionnaire, all but two patients
Table 2 Comorbidities
Comorbidity Amount (n)
Heart failure 9
Diabetes 14
Chronic renal failure 0
Hypertension 26
CVA/TIA 1
Myocardial infarction 1
Angina 1
Pulmonary hypertension 4
CVA, cerebral vascular accident; TIA, transient ischaemic attack.
Figure 2 (A) Time to ﬁrst exacerbation requiring hospital admission
telemonitoring versus control for the overall results. (B) Time to ﬁrst
exacerbation requiring hospitalisation in COPD and non-COPD groups.
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reported using the equipment after demonstration ‘was not a
problem’; the remaining two found the instructions ‘a little hard
to follow’.
Table 5 shows the number of telephone consults and the
alerts generated per month. The majority of alerts were related
to SpO2 levels.
DISCUSSION
This randomised crossover trial showed telemonitoring did not
lengthen time to next exacerbation requiring acute hospitalisa-
tion; indeed, admission rate for acute exacerbations and home
visits increased. Quality of life measured by EQ-5D generic
scores did not improve during telemonitoring and self-efﬁcacy
fell during the trial but particularly in those using telemonitor-
ing ﬁrst. The only improvement was a lower HADS depression
score during telemonitoring, although the signiﬁcance of this is
questionable as it represents a change of only 0.53 units in
patients who, on average, were not clinically depressed and is
less than the minimal clinically important difference.17 HAD
anxiety score did not change.
Interpretation of ﬁndings in the context of previously
published work
The present study showed an increase in healthcare activity gen-
erated by telemonitoring, which was not expected. Although
time to ﬁrst readmission for acute exacerbation did not change,
actual admissions doubled from 18 to 36 and there was a sub-
stantial increase in home visits. We acknowledge that the criteria
for hospital admission are dependent on local hospital policy as
not all patients were directly admitted to our centre. However,
like Pinnock and coworkers,10 we cross-referenced all admis-
sions with discharge summaries to ensure that admission was
due to an acute exacerbation. Home visits were carried out if
the patient was not responding to telephone advice. The explan-
ation for this increase in healthcare activity including home
visits and the absence of reduction in hospital admissions seen
in other telemonitoring trials may be due to the reduction in
self-efﬁcacy. This may cause patients to rely more heavily on the
telemonitoring team who instigated more reviews both using
home visits and hospital visits. Indeed, the potential for telemo-
nitoring to increase reliance on healthcare professionals has also
been reported in COPD and asthma by others.18 19 This is the
opposite of the intended effect of improving patients’ ability to
self-care, thereby reducing admissions and healthcare activity,
and improving quality of life. The main triggers for a home visit
were fall in SpO2, accompanied by symptoms. Variation in SpO2
can be helpful in predicting exacerbations and may be valuable
in patients who fail to recognise the development of an exacer-
bation, and therefore, seek treatment late.20 Predictive compos-
ite scores of heart rate variation and SpO2 have been developed
in patients with COPD with mild desaturation at rest.21 By
selecting more severe patients using LTOT or having an SpO2
<90% on air during index admission in the TeleCRAFT trial,
this baseline hypoxaemia (SpO2 mean (SD) 92 (3)% in patients
with COPD and 89 (6)% in non-COPD patients) meant that
more marked variation in SpO2 occurred as SpO2 was on the
steep descent of the oxygen dissociation curve. Our expectation
was that day-to-day variation in this more hypoxemic group will
be greater, making it more likely that intervention would be
prompted by the healthcare team observing daily data. A better
understanding of day-to-day variation of SpO2 in this severely
compromised respiratory population would be helpful and
might decrease home visits and hospitalisations. However, pat-
terns of exacerbation tend to show more variation between indi-
viduals rather than within individuals, making algorithms in
practice only weakly predictive.22 Teams may gain more under-
standing of diurnal variation in variables as their experience
with telemonitoring in individual users increases. This ﬁnding
also exempliﬁes the fact that more data can be helpful, but can
also add to clinical uncertainty and therefore precipitate more
activity. Increased healthcare activity and home visits in turn
may act as a deterrent to the patient taking responsibility for
his/her disease and may lead to co-dependency between patient
and healthcare team.
Limitations of study
Our patients are of a similar age to that of Vitacca and cowor-
kers,5 and we included a similar proportion using long-term
NIV. This extent of NIV use may not occur in other units. We
ensured all patients were optimally treated with NIV prior to
entering the study and no patient started LTOT or NIV during
the study. Although the age is slightly younger than that in the
trial of Pinnock and coworkers,10 COPD recruits had a similar
mean GOLD stage. The majority of patients were recruited
within the ﬁrst two months after a hospital exacerbation. Our
patient group was characterised by being hypoxaemic during an
exacerbation or on LTOT. We selected this group of patients
that were hypoxic on admission or on LTOTwith the hypothesis
that oximetry would be the most helpful and discriminating
Table 3 Six-month healthcare activity
Control Telemonitoring Difference
N Mean Mean Mean (SE) p Value
Respiratory hospital
admissions
57 0.32 0.63 0.32 (0.14) 0.026
Home visits 52 0.75 4.00 3.25 (0.81) <0.001
Hospital visits 49 3.23 3.79 0.56 (0.65) 0.394
GP visits 49 5.17 5.75 0.58 (1.03) 0.573
GP, general practitioner; N, number in analysis.
Table 4 Health-related quality of life and self-efficacy scores
Control Telemonitoring Difference
N Mean Mean Mean (SE) p-Value
HAD anxiety score 47 7.98 8.25 −0.28 (0.3) 0.364
HAD depression
score
47 6.9 6.37 0.53 (0.26) 0.046
Stanford score 46 5.82 5.18 0.64 (0.19) 0.001
EQ-5D scale score 53 59.6 57.85 1.75 (1.57) 0.270
HAD, hospital anxiety and depression score; N, number in analysis.
Table 5 Number of telephone consults and patient-related alerts
generated
Consults and alerts Number per month
Total telephone consults 29
Total telephone consults for low SpO2 18
Total alerts due to SpO2 187
Total ‘red’ alerts due to SpO2 31
Total out-of-range tasks 337
Total ‘red’ alerts 460
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observation. Most importantly, this group represents our clinical
case load and we wanted to evaluate the role of telemonitoring
in this group. While we still feel that our results are applicable
elsewhere, the ﬁndings cannot be generalised to those with
milder chronic respiratory disease who are normoxaemic.
The sample size was calculated at 63, and while 72 patients
were entered, 61 patients completed the study. This reduces the
power of the trial, but it seems unlikely that additional patients
would have altered the outcome.
A perceived limitation of the study is that team members
managing the patients knew whether they were in telemonitor-
ing or control limb as they had telemonitoring data available to
them, so were not blinded to the intervention. However, like
Vitacca and coworkers,5 we monitored our patients for 40 h per
week. Our patients also had contact telephone numbers of com-
munity team members for contact at weekends and evenings.
Unlike the Vitacca et al5 trial, our telemonitoring team knew
the patients and were familiar with their respiratory status. We
felt that this would help prevent unnecessary home visits or
over-identiﬁcation of exacerbations. It maybe also be seen as a
limitation not having 24/7 care, but one of the aims of telemoni-
toring is to promote independence and self-management rather
than reliance on healthcare professionals. This outcome was not
supported by the results of this study. The fact that the control
group had access to phone support may not be standard in
other centres and could mitigate any additional effects of
telemonitoring.
A further criticism of the present study is that we did not
include a washout period. However, the aim of the present
study was for the patient to act as their own control to see
whether education and management during telemonitoring
improved self-efﬁcacy. Therefore, we do not believe that there is
a sensible length of washout period as patients may or may not
gain knowledge from the telemonitoring about management of
exacerbations, which they may retain for variable periods of
time. A washout period could, therefore, be 1 week, 1 month,
6 months or more according to individual variation, and during
this period deterioration in overall clinical status could occur.
For that carefully considered reason, a washout period was not
included in the trial design.
An addition consideration is that the duration of monitoring
and control periods was 6 months, which could be impacted
upon by seasonal variations in exacerbations, despite randomisa-
tion of patients to each arm.
We used a second-generation telemonitoring system-this is a
non-immediate or analytical decision system where the data
transfer is synchronous with an automated algorithm. The team
recognises important changes in the patient’s condition but
delays in response can occur if the system is only monitored at
certain times. By comparison, third-generation systems have
constant analytical and decision-making support in which moni-
toring centres are physician led, staffed by specialist nurses and
have full authority to effect therapy changes 24 h per day,
7 days per week. We chose to use the Phillips Motiva system as
it was available to us at the start of the trial and had been suc-
cessfully deployed in the Whole System Demonstrator trial.
While third-generation systems might offer advantages in
theory, to date there is no evidence that one system is better
than another in practice.
Managing telemonitoring data
A key issue with monitoring systems is the generation of ‘too
much information’ due to a lack of appropriately sensitive and
speciﬁc algorithms. This continues to be one of the main
challenges for telemonitoring in respiratory disease and is high-
lighted in our results by the number of out-of-range alerts and
high number of ‘red’ alerts generated related to SpO2 levels.
This was despite individualised setting of the target levels by the
healthcare team. A similar ﬁnding of frequent sampling of
physiological data prompting increased interventions was
observed in the DOT-HF trial23 in which the use of an
intrathoracic impedance monitoring device to closely track ﬂuid
balance in patients with heart failure resulted in an almost three-
fold increase in outpatient visits and 79% increase in heart
failure admissions.
Signiﬁcance of telemonitoring and the future
Our results differ very signiﬁcantly from those of Vitacca et al5
who showed in a group of patients with COPD and non-COPD
patients that telemonitoring produced a reduction in healthcare
activity. However, the Bilbao trial generated more telephone
calls to patients in the telemonitoring group,6 while both the
WSD trial9 and Edinburgh trial10 showed no reduction in
healthcare activity. It is notable that the two largest trials to date
of telemonitoring in heart failure2 3 showed no change in
healthcare utilisation. There is growing evidence that the impact
of telemonitoring will depend on the integration of this process
with existing care pathways, and links between the patient, GP,
community and hospital teams. If there is a clearly identiﬁed
pathway already operating and care has been optimised, telemo-
nitoring may not have much to add, and as shown here may
intensify workload by generating further healthcare visits to
check telemonitoring data. However, in situations where the
home network is less well established, telemonitoring may have
more to contribute. Telemonitoring may be more relevant in
patients who are widely dispersed geographically, for example.
Although in TeleCRAFT we did not ﬁnd that socially isolated
patients beneﬁtted more greatly from telemonitoring compared
with patients with a home relative or carer. Furthermore, there
may be advantages to using telemonitoring in patients who have
poor access to hospital because of mobility problems, for
example, housebound individuals or those with progressive con-
ditions such as motor neurone disease/amyotropic lateral scler-
osis (MND/ALS).
CONCLUSIONS
The results of the TeleCRAFT trial suggest that the application
of telemonitoring using a second-generation system in patients
with chronic respiratory failure increased healthcare activity,
without generating an improvement in quality of life for the
patient. Consideration should be given to the investigation of
targeting this resource to particular subgroups rather than an
unfocussed widespread application in chronic respiratory
disease.
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